Kv3 Channel Modulator Compounds for Potency and Safety Balance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for alternative modulators of Kv3.1, Kv3.2, and/or Kv3.3 channels that demonstrate high in vivo potency, channel selectivity, improved safety profiles, and desirable pharmacokinetic parameters, such as high brain availability and low clearance rates, to effectively treat conditions like hearing disorders, tinnitus, schizophrenia, pain, and Fragile X syndrome.
Innovation Solution
Development of novel compounds of formula (I), including pharmaceutically acceptable salts and solvates, which modulate Kv3 channels, particularly Kv3.1 and/or Kv3.2, to address these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Kv3 channel modulators are used, then channel modulation effect is achieved, but in vivo potency and safety profiles are insufficient
Solution Approach 1:
The patent modifies chemical parameters of Kv3 channel modulators by changing substituents at specific positions (R1, R2, R3, R4, R5 groups) to optimize the balance between in vivo potency and safety profile. This involves systematic variation of molecular structure parameters to achieve desired pharmacological properties
Solution Approach 2:
The patent develops composite molecular structures combining different functional groups (hydantoin core with various aromatic substituents) to create modulators that simultaneously achieve high potency and improved safety. The composite structure integrates multiple pharmacophores that work synergistically
2Ease of operation
If existing modulators are used, then some therapeutic effect is achieved, but brain availability and clearance rates are not optimal
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by modifying molecular weight, lipophilicity, and hydrogen bonding capacity through strategic selection of substituents. These parameter changes improve blood-brain barrier penetration while reducing metabolic clearance
Solution Approach 2:
The patent replaces suboptimal pharmacokinetic properties of existing modulators with improved molecular structures that naturally achieve better brain availability and slower clearance without requiring mechanical delivery systems or formulations
3Measurement precision
If channel selectivity is increased, then specific Kv3 subtype modulation is improved, but overall therapeutic efficacy may be reduced
Solution Approach 1:
The patent applies local quality by designing modulators with specific substituent patterns that target particular Kv3 subtypes (Kv3.1, Kv3.2, or Kv3.3) while maintaining overall therapeutic efficacy. Different R-group combinations provide selective interaction with specific channel subtypes expressed in different brain regions
Solution Approach 2:
The patent creates multi-functional modulators that can selectively modulate different Kv3 subtypes depending on the substituent configuration. The core hydantoin structure provides universal Kv3 channel binding while substituents confer subtype selectivity, allowing one scaffold to address multiple therapeutic needs
Data Source
AI summary
Disclosed is a compound of formula (I):wherein R1 is H or methyl, R2 and R3 are both methyl, or R2 and R3, together with the carbon atom to which they are attached, are a spirocyclopropyl ring, R4 is methyl or ethyl, R5 is H or methyl, or R4 and R5, together with the carbon atom to which they are attached, form a C3-C4 spiro carbocyclyl. Also disclosed are methods for treating and/or preventing one or more diseases or disorders comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate and/or derivative thereof. Additionally, methods using a compound of formula (I) to manufacture medicaments are provided.